Galcanezumab (Emgality)

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses galcanezumab (Emgality), 120 mg/mL solution for subcutaneous injection. Indication: For the prevention of migraine in adults who have at least 4 migraine days per month.